Financial Comparison: Juniper Pharmaceuticals (JNP) vs. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)

Juniper Pharmaceuticals (NASDAQ: JNP) and Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Volatility and Risk

Juniper Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corporation has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Juniper Pharmaceuticals and Adamis Pharmaceuticals Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Adamis Pharmaceuticals Corporation 0 0 2 0 3.00

Juniper Pharmaceuticals presently has a consensus price target of $17.58, suggesting a potential upside of 286.45%. Adamis Pharmaceuticals Corporation has a consensus price target of $7.50, suggesting a potential upside of 63.04%. Given Juniper Pharmaceuticals’ higher possible upside, equities analysts plainly believe Juniper Pharmaceuticals is more favorable than Adamis Pharmaceuticals Corporation.

Institutional & Insider Ownership

36.6% of Juniper Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.6% of Adamis Pharmaceuticals Corporation shares are owned by institutional investors. 11.6% of Juniper Pharmaceuticals shares are owned by company insiders. Comparatively, 9.6% of Adamis Pharmaceuticals Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Juniper Pharmaceuticals and Adamis Pharmaceuticals Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 13.94% 21.49% 14.40%
Adamis Pharmaceuticals Corporation -158.51% -69.03% -47.51%

Valuation and Earnings

This table compares Juniper Pharmaceuticals and Adamis Pharmaceuticals Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Juniper Pharmaceuticals $57.69 million 0.86 $9.49 million $0.74 6.15
Adamis Pharmaceuticals Corporation $11.39 million 11.13 -$18.97 million N/A N/A

Juniper Pharmaceuticals has higher revenue and earnings than Adamis Pharmaceuticals Corporation.

Summary

Juniper Pharmaceuticals beats Adamis Pharmaceuticals Corporation on 9 of the 11 factors compared between the two stocks.

Juniper Pharmaceuticals Company Profile

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Adamis Pharmaceuticals Corporation Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

What are top analysts saying about Juniper Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juniper Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit